Related Experiment Videos
Tamoxifen for retroperitoneal fibrosis
L Frankart1, F Lorge, J Donckier
1Division of Internal Medicine and Endocrinology, University Hospital UCL of Mont-Godinne, Yvoir, Belgium.
Postgraduate Medical Journal
|March 14, 1998
Summary
Retroperitoneal fibrosis, a chronic fibrotic disease, can obstruct ureters and vessels. This case study shows successful treatment of aortic inflammatory aneurysm-associated retroperitoneal fibrosis using oral tamoxifen.
Area of Science:
- Fibrotic diseases
- Vascular inflammation
- Ureteral obstruction
Background:
- Retroperitoneal fibrosis (RPF) is a chronic fibrotic condition.
- RPF can be idiopathic or linked to aortic inflammatory aneurysms.
- It leads to progressive ureteral and vascular obstruction in the lower abdomen.
Observation:
- A patient presented with RPF associated with an aortic inflammatory aneurysm.
- Traditional treatments like surgery or steroids pose significant risks.
Findings:
- The patient was successfully treated with oral tamoxifen.
- Tamoxifen offers a potential alternative therapeutic approach.
Implications:
- This case suggests tamoxifen as a viable treatment option for RPF.
- Further research may explore tamoxifen's efficacy in similar fibrotic conditions.